Related Experiment Video
Updated: Aug 14, 2025

Characterizing Exon Skipping Efficiency in DMD Patient Samples in Clinical Trials of Antisense Oligonucleotides
Published on: May 7, 2020
Eteplirsen Use in a Boy with Duchenne Muscular Dystrophy and Sickle Cell Anemia
Gregory M Aiello1, Michael Stephen Cartwright2
1Wake Forest School of Medicine, Winston-Salem, North Carolina, USA.
Abstract:
Eteplirsen is an antisense oligonucleotide used in the treatment of Duchenne muscular dystrophy (DMD). The safety of eteplirsen use in individuals with rare comorbid conditions is not known. We present the case of a 4-year-old boy with a DMD exon deletion amenable to treatment with eteplirsen and comorbid sickle cell anemia. He has received eteplirsen treatment for 3 years with no clear adverse effects, including no increase in sickle cell crises.
More Related Videos
07:44CRISPR/Cas9 Technology in Restoring Dystrophin Expression in iPSC-Derived Muscle Progenitors
Published on: September 14, 2019
08:13Purification and Transplantation of Myogenic Progenitor Cell Derived Exosomes to Improve Cardiac Function in Duchenne Muscular Dystrophic Mice
Published on: April 10, 2019
Related Concept Videos
Satellite Stem Cells and Muscular Dystrophy
iPS Cell Differentiation
EPS and iPS Cells in Disease Research
01:08Gene Therapy
Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin
The binding of dantrolene to the RYR1...
Skeletal Muscle Relaxants: Therapeutic Uses